Targeted Therapy Combined with Immune Checkpoint Therapy: Is This the Wave of the Future?
Jean H. Hoffman-Censits, MD explores combining targeted therapy with immune checkpoint therapy to treat bladder cancer.
Read MoreSelect Page
Jean Hoffman-Censits, MD, is Associate Professor of Medical Oncology and Urology at The Johns Hopkins University School of Medicine. Dr. Hoffman-Censits earned her medical degree at The Sidney Kimmel Medical College at Thomas Jefferson University, where she completed her internal medicine residency and chief residency. She completed her oncology training at Fox Chase Cancer Center, then returned to Jefferson as a genitourinary (GU) medical oncologist, leading their multidisciplinary GU oncology clinic. She joined the Johns Hopkins Greenberg Bladder Cancer Institute in 2018 as the co-leader of the Women’s Bladder Cancer Program and Upper Tract Urothelial Cancer (UTUC) Multidisciplinary Clinic.
Dr. Hoffman-Censits’ research interests have focused on development of novel therapeutics for urothelial cancers. Her collaborations led to the first U.S. Food and Drug Administration (FDA) approval of systemic immunotherapy for urothelial cancer, supported accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as a standard preoperative regimen, and helped define biomarkers of chemotherapy response. Integral to the success of the first multicenter trial of preoperative chemotherapy in upper tract urothelial cancer, Dr. Hoffman-Censits is leading a Phase III neoadjuvant chemo immunotherapy trial in the cooperative groups. She continues to develop novel trials for bladder, upper tract, as well as small-cell bladder cancers.
Posted by Jean Heather Hoffman-Censits, MD | Dec 2022
Jean H. Hoffman-Censits, MD explores combining targeted therapy with immune checkpoint therapy to treat bladder cancer.
Read MorePosted by Jean Heather Hoffman-Censits, MD | Dec 2022
Jean H. Hoffman-Censits, MD, focuses on studies of PD-1 and PD-L1 inhibitors combined with other agents in bladder cancer treatment.
Read More